Who
Raymond Debbane
Director
Company insider
Files Form 4 as: Director and 10% owner, Lexicon Pharmaceuticals; Director and Other, WW International; Director, Blue Buffalo Pet Products; Director, Ceres; 10% owner, Nitromed.
In numbers
- Trades disclosed
- 222
- Buys
- 20
- Sells
- 0
- Bought
- $125.1M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 15 Dec 2006
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 25 Feb 2026filed 27 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $2,9802,000 at $1.49 | filing |
| 25 Feb 2026filed 27 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $2,9802,000 at $1.49 | filing |
| 23 Feb 2026filed 25 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $147K100,000 at $1.47 | filing |
| 23 Feb 2026filed 25 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $147K100,000 at $1.47 | filing |
| 20 Feb 2026filed 23 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $148K100,000 at $1.48 | filing |
| 20 Feb 2026filed 23 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $148K100,000 at $1.48 | filing |
| 19 Feb 2026filed 23 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $72K50,000 at $1.44 | filing |
| 19 Feb 2026filed 23 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $72K50,000 at $1.44 | filing |
| 18 Feb 2026filed 18 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $176K133,688 at $1.32 | filing |
| 18 Feb 2026filed 18 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $176K133,688 at $1.32 | filing |
| 17 Feb 2026filed 18 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $101K76,857 at $1.31 | filing |
| 17 Feb 2026filed 18 Feb 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $101K76,857 at $1.31 | filing |
News
No headline names them, or the companies they trade most, lately.